한글목차

세계 인공 췌장 시스템 시장 규모는 2024년에 4억 5,697만 달러에 달했습니다. 2033년에는 63억 470만 달러에 달할 것으로 예상되며, 예측 기간인 2025-2033년에는 30.0%의 연평균 복합 성장률(CAGR)을 보일 전망입니다.

인공 췌장 시스템은 1형 당뇨병 환자의 혈당 조절을 자동화하는 의료기기입니다. 지속적 혈당 모니터, 인슐린 펌프, 고급 제어 알고리즘을 포함합니다. 이 시스템은 건강한 췌장의 기능을 모방하여 최적의 혈당 수준을 보장하고 고혈당 및 저혈당 위험을 줄입니다. 당뇨병 관리와 환자의 편의성을 향상시키고 수동 인슐린 투여의 필요성을 최소화합니다.

시장 역학

성장 촉진요인과 억제요인

당뇨병 유병률 증가

세계 당뇨병 유병률, 특히 1형 당뇨병의 유병률이 인공 췌장 시스템 시장을 주도하고 있습니다. 많은 당뇨병 환자들은 지속적인 혈당 관리가 필요하며, 이는 자동화 솔루션에 대한 수요로 이어지고 있습니다. 센서 기술의 발전으로 인슐린 투여가 개선되고, AI 기반 알고리즘이 효율적인 개인 맞춤형 당뇨병 관리 솔루션을 제공함으로써 시장 성장에 기여하고 있습니다.

예를 들어, IDF에 따르면 2045년까지 당뇨병 유병률이 46% 증가하여 90% 이상이 2형 당뇨병이 될 것으로 예측했습니다. 이러한 증가의 요인은 도시화, 고령화, 신체활동 감소, 과체중과 비만 증가이며, 이는 사회경제적, 인구통계학적, 환경적, 유전적 요인에 의해 악화되고 있습니다.

따라서 당뇨병 유병률 증가는 인공 췌장 장치 시스템에 대한 수요를 촉진할 것입니다. 이러한 수요와 도시화 및 생활습관 관련 위험요인으로 인해 고급 포도당 관리 솔루션이 필요하며, 이는 자동 인슐린 투여 시장 확대로 이어질 것입니다.

인공 췌장 시스템의 높은 비용

인공 췌장 시스템은 당뇨병 관리의 잠재적 이점에도 불구하고, 특히 중저소득 국가에서 시장 확대에 큰 장벽에 직면해 있습니다. 고급 부품의 높은 비용, 제한된 상환 정책, 높은 유지보수 비용이 채택을 더욱 제한하고 보급을 제한하고 있습니다. 예를 들어, Tandem t:slim X2 Pump(Control-IQ 포함)의 가격은 약 4,000 달러이며, 일반적으로 보험은 가격의 80%를 보장합니다. 트랜스미터 및 센서 등 Dexcom G6 CGM의 소모품에 대한 추가 비용은 고가일 수 있습니다.

이 보고서는 세계 인공 췌장 시스템 시장에 대해 조사했으며, 시장 역학, 지역 및 부문 분석, 경쟁 구도, 기업 프로파일 등의 정보를 전해드립니다.

목차

제1장 시장 서론과 범위

제2장 주요 인사이트와 중요 사항

제3장 시장 하이라이트와 전략적 포인트

• 주요 동향과 향후 예측
• 발췌 : 디바이스 유형별
• 발췌 : 최종사용자별
• 발췌 : 지역별

제4장 시장 역학

• 영향요인
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 영향 분석

제5장 전략적 인사이트와 산업 전망

• 시장 리더와 선구자
  • 신흥 선구자와 저명 기업
  • 기존 리더와 가장 많이 판매되는 브랜드
  • 시장 리더와 기존 제품
• CXO의 견해
• 최신 발전과 Break through
• 사례 연구/진행중인 조사
• 규제와 상환 상황
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카
• Porter의 Five Forces 분석
• 공급망 분석
• 특허 분석
• SWOT 분석
• 미충족 요구와 갭
• 시장 진입 및 확장을 위한 권장 전략
• 시나리오 분석 : 베스트 케이스, 기본 케이스, 워스트 케이스 예측
• 가격 분석과 가격 동향
• KOL(Key Opinion Leader)

제6장 디바이스 유형별

• Threshold Suspend Device Systems
• 인슐린 시스템
• 듀얼 호르몬 시스템

제7장 최종사용자별

• 병원
• 진료소
• 홈케어 환경
• 외래수술센터(ASC)

제8장 지역 시장 분석과 성장 기회

제9장 서론

• 북미
  • 주요 지역 특유 동향
    • 미국
    • 캐나다
• 유럽
  • 주요 지역 특유 동향
    • 독일
    • 영국
    • 프랑스
    • 스페인
    • 이탈리아
    • 기타 유럽
• 라틴아메리카
  • 주요 지역 특유 동향
    • 멕시코
    • 브라질
    • 아르헨티나
    • 기타 라틴아메리카
• 아시아태평양
  • 주요 지역 특유 동향
    • 중국
    • 인도
    • 일본
    • 한국
    • 기타 아시아태평양
• 중동 및 아프리카
  • 주요 지역 특유 동향

제10장 경쟁 구도와 시장 포지셔닝

• 경쟁 구도 개요와 주요 시장 기업
  • 시장 점유율 분석과 포지셔닝 매트릭스
  • 전략적 파트너십 및 인수합병(M&A)
  • 제품 포트폴리오와 혁신 주요 발전
  • 기업 벤치마킹

제11장 기업 개요

• Medtronic Plc
• Tandem Diabetes Care, Inc
• Beta Bionics
• Insulet Corporation
• Diabeloop
• Inreda Diabetic BV
• Nikkiso Co., Ltd(LIST NOT EXHAUSTIVE)

제12장 전제조건과 조사 방법

제13장 부록

영문목차

The global artificial pancreas system market reached US$ 456.97 million in 2024 and is expected to reach US$ 6304.70 million by 2033, growing at a CAGR of 30.0% during the forecast period 2025-2033.

Artificial pancreas system is a medical device that automates blood glucose control in type 1 diabetes patients. It includes a continuous glucose monitor, insulin pump, and advanced control algorithm. This system mimics the function of a healthy pancreas, ensuring optimal blood sugar levels and reducing the risk of hyperglycemia and hypoglycemia. It improves diabetes management and patient convenience and minimizes the need for manual insulin administration.

Market Dynamics: Drivers & Restraints

Rising Prevalence of Diabetes

The global diabetes prevalence, particularly type 1, is driving the artificial pancreas system market. Many diabetes patients need continuous blood glucose management, leading to a demand for automated solutions. Advancements in sensor technology improved insulin delivery, and AI-driven algorithms are contributing to market growth by offering efficient, personalized diabetes management solutions.

For instance, according to International Diabetes Foundation by 2045, IDF projections indicate a 46% increase in diabetes prevalence, with over 90% of individuals having type 2 diabetes. Factors contributing to this increase include urbanization, an aging population, decreased physical activity, and an increase in overweight and obesity, which are exacerbated by socio-economic, demographic, environmental, and genetic factors.

Hence, an increase in the prevalence of diabetes will drive demand for artificial pancreas device systems. This demand, coupled with urbanization and lifestyle-related risk factors, necessitates advanced glucose management solutions, leading to market expansion for automated insulin delivery.

High Cost of Artificial Pancreas Systems

Artificial pancreas systems, despite their potential benefits in diabetes management, face significant barriers to market expansion, particularly in low- and middle-income countries. The high cost of advanced components, limited reimbursement policies, and high maintenance costs further restrict adoption, limiting their widespread use. For instance, The Tandem t:slim X2 pump with Control-IQ costs around $4,000, with insurance typically covering 80% of the cost. Additional costs for Dexcom G6 CGM supplies, such as a transmitter and sensors, can be significant.

Segment Analysis

The global artificial pancreas system market is segmented based on device type, end-user, and region.

Device Type:

The threshold suspend device systems from the device type segment is expected to dominate the artificial pancreas system market with the highest market share

The threshold suspend and predictive suspend systems are tools that temporarily suspend insulin delivery when blood glucose levels drop below a pre-set level. These systems calculate blood glucose levels and stop delivering insulin before they reach too low. They do not automatically increase insulin doses. Storing insulin at the right moment can help prevent low blood sugar, or hypoglycemia, in individuals with type 1 diabetes. These systems may also assist those who develop hypoglycemia overnight, especially children.

The rise in diabetes, particularly type 1, is driving the adoption of Threshold Suspend Device Systems. This is driven by increased awareness of hypoglycemia risks and the need for automated insulin delivery systems. Technological advancements, regulatory approvals, healthcare expenditure, and expanded reimbursement policies in developed regions contribute to the adoption of these life-saving devices.

Geographical Analysis

North America is expected to hold a significant position in the artificial pancreas system market with the highest market share

North America dominates the threshold suspend device systems market due to advanced healthcare infrastructure, high diabetes management technologies, and key market players. The region's large type 1 diabetes population drives demand for automated insulin delivery solutions. Benefits from reimbursement policies, continuous glucose monitoring awareness, and technological advancements in insulin pumps drive market growth. Government initiatives, increased healthcare expenditure, and personalized medicine focus contribute to the growing adoption of Threshold Suspend Device Systems in North America.

Moreover, FDA approvals are also a significant factor that helps the region to grow during the forecast period. For instance, in May 2024, The U.S. Food and Drug Administration (FDA) approved an artificial pancreas developed by University of Cambridge researchers for use by individuals with type 1 diabetes, including during pregnancy, marking the first time the FDA has authorized the use of this life-changing app during pregnancy.

Moreover, in May 2023, the FDA approved the iLet Insulin-Only Bionic Pancreas System for individuals aged 6 and above with type 1 diabetes, an artificial pancreas system that autonomously determines and delivers insulin doses.

Competitive Landscape

The major global players in the artificial pancreas system market include Medtronic Plc, Tandem Diabetes Care, Inc., Beta Bionics, Insulet Corporation, Diabeloop, Inreda Diabetic B.V., and Nikkiso Co., Ltd among others.

Key Developments

• In April 2024, the NHS launched a world-first initiative for tens of thousands of children and adults with type 1 diabetes in England, which will use an 'artificial pancreas' to monitor blood glucose levels and automatically adjust insulin dosage.

Why Purchase the Report?

• Technological Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global artificial pancreas system market report delivers a detailed analysis with 45key tables, more than 40 visually impactful figures and 165 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Application & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

• 1.1. Objectives of the Report
• 1.2. Report Coverage & Definitions
• 1.3. Report Scope

2. Executive Insights and Key Takeaways

3. Market Highlights and Strategic Takeaways

• 3.1. Key Trends and Future Projections
• 3.2. Snippet by Device Type
• 3.3. Snippet by End-User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising Prevalence of Diabetes
    • 4.1.1.2. Growing Adoption of Wearable and AI-driven Healthcare Devices
  • 4.1.2. Restraints
    • 4.1.2.1. High Cost of Artificial Pancreas Systems
    • 4.1.2.2. Stringent Regulatory Requirements and Approval Delays
  • 4.1.3. Opportunity
    • 4.1.3.1. Integration of AI and Machine Learning for Personalized Diabetes Management
  • 4.1.4. Impact Analysis

5. Strategic Insights and Industry Outlook

• 5.1. Market Leaders and Pioneers
  • 5.1.1. Emerging Pioneers and Prominent Players
  • 5.1.2. Established leaders with largest selling Brand
  • 5.1.3. Market leaders with established Product
• 5.2. CXO Perspectives
• 5.3. Latest Developments and Breakthroughs
• 5.4. Case Studies/Ongoing Research
• 5.5. Regulatory and Reimbursement Landscape
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa
• 5.6. Porter's Five Force Analysis
• 5.7. Supply Chain Analysis
• 5.8. Patent Analysis
• 5.9. SWOT Analysis
• 5.10. Unmet Needs and Gaps
• 5.11. Recommended Strategies for Market Entry and Expansion
• 5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 5.13. Pricing Analysis and Price Dynamics
• 5.14. Key Opinion Leaders

6. By Device Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
  • 6.1.2. Market Attractiveness Index, By Device Type
• 6.2. Threshold Suspend Device Systems*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Insulin-only Systems
• 6.4. Dual Hormone Systems

7. By End-User

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 7.1.2. Market Attractiveness Index, By End-User
• 7.2. Hospitals*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Clinics
• 7.4. Homecare Settings
• 7.5. Ambulatory Surgical Centers

8. Regional Market Analysis and Growth Opportunities

9. Introduction

• 9.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.1. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.5.1. U.S.
    • 9.2.5.2. Canada
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.5.1. Germany
    • 9.3.5.2. U.K.
    • 9.3.5.3. France
    • 9.3.5.4. Spain
    • 9.3.5.5. Italy
    • 9.3.5.6. Rest of Europe
• 9.4. Latin America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.5.1. Mexico
    • 9.4.5.2. Brazil
    • 9.4.5.3. Argentina
    • 9.4.5.4. Rest of Latin America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.5.1. China
    • 9.5.5.2. India
    • 9.5.5.3. Japan
    • 9.5.5.4. South Korea
    • 9.5.5.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape and Market Positioning

• 10.1. Competitive Overview and Key Market Players
  • 10.1.1. Market Share Analysis and Positioning Matrix
  • 10.1.2. Strategic Partnerships, Mergers & Acquisitions
  • 10.1.3. Key Developments in Product Portfolios and Innovations
  • 10.1.4. Company Benchmarking

11. Company Profiles

• 11.1. Medtronic Plc*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio
    • 11.1.2.1. Product Description
    • 11.1.2.2. Product Key Performance Indicators (KPIs)
    • 11.1.2.3. Historic and Forecasted Product Sales
    • 11.1.2.4. Product Sales Volume
  • 11.1.3. Financial Overview
    • 11.1.3.1. Company Revenue's
    • 11.1.3.1.1. Geographical Revenue Shares
    • 11.1.3.1.1.1. Revenue Forecasts
    • 11.1.3.1.2. Key Developments
    • 11.1.3.1.2.1. Mergers & Acquisitions
    • 11.1.3.1.2.2. Key Product Development Activities
    • 11.1.3.1.2.3. Regulatory Approvals, etc.
    • 11.1.3.1.3. SWOT Analysis
• 11.2. Tandem Diabetes Care, Inc
• 11.3. Beta Bionics
• 11.4. Insulet Corporation
• 11.5. Diabeloop
• 11.6. Inreda Diabetic B.V
• 11.7. Nikkiso Co., Ltd(LIST NOT EXHAUSTIVE)

12. Assumption and Research Methodology

• 12.1. Data Collection Methods
• 12.2. Data Triangulation
• 12.3. Forecasting Techniques
• 12.4. Data Verification and Validation

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us